A Phase 3 interventional study of Mirikizumab IV and Mirikizumab SC in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 34 sites in 11 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 11th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 9th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Rubix LS · Sites in United States
Ages 60–99
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2023.
This study's enrollment of 63 is close to the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 172 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
16 studies in Colitis, Ulcerative by Eli Lilly and Company: 5 open now, 7 under way, 3 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 12th largest by enrollment, is one of 2 that started in 2023, is one of 8 in phase 3, and was the 11th registered.
Eli Lilly and Company’s Colitis, Ulcerative studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 16 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Participants who complete the study will have the option to enter the long-term extension Study I6T-MC-AMAZ (AMAZ).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: Participants will receive mirikizumab weight-based dosing intravenously (IV) or subcutaneously (SC).
Drug: Mirikizumab IV · Drug: Mirikizumab SC
Experimental: Participants will receive mirikizumab weight-based dosing IV or SC.
Drug: Mirikizumab IV · Drug: Mirikizumab SC
Experimental: Mirikizumab Participants will receive mirikizumab weight-based dosing IV or SC.
Drug: Mirikizumab IV · Drug: Mirikizumab SC
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Percentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical Responders
Time frame: Baseline to Week 52
Percentage of Participants in MMS Clinical Remission
Time frame: Week 12
Percentage of Participants in MMS Clinical Response
Time frame: Week 12
Percentage of Participants with Endoscopic Remission
Time frame: Week 12
Percentage of Participants with Endoscopic Improvement
Time frame: Week 12
Percentage of Participants Achieving Pediatric Ulcerative Colitis Activity Index (PUCAI) Clinical Response
Time frame: Week 12
Percentage of Participants Achieving PUCAI Clinical Remission
Time frame: Week 12
Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement
Time frame: Week 12
Percentage of Participants Achieving MMS Clinical Response
Time frame: Week 52
Percentage of Participants Achieving MMS Clinical Remission
Time frame: Week 52
Percentage of Participants Achieving PUCAI Clinical Response
Time frame: Week 52
Percentage of Participants Achieving PUCAI Clinical Remission
Time frame: Week 52
Percentage of Participants Achieving Endoscopic Remission
Time frame: Week 52
Percentage of Participants Achieving Endoscopic Improvement
Time frame: Week 52
Percentage of Participants Achieving MMS Clinical Remission without Surgery at Week 52 among Clinical Responders at Week 12 and without the Use of Corticosteroids
Time frame: Baseline to Week 52
Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement
Time frame: Week 52
Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab
PK: AUC of Mirikizumab
Time frame: Baseline to Week 52
PK: Cmax of Mirikizumab
Time frame: Baseline to Week 52
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2023 to primary completion in May 2026, 29 months.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 29 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab